Current Rating and Its Significance
MarketsMOJO’s 'Buy' rating for Venus Remedies Ltd indicates a positive outlook on the stock, suggesting that investors may consider adding or holding the stock in their portfolios. This rating reflects a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical indicators. The upgrade from 'Hold' to 'Buy' on 12 Nov 2025 was driven by improvements across these parameters, but it is essential to understand how the stock stands today with the most recent data.
Here’s How Venus Remedies Ltd Looks Today
As of 24 December 2025, Venus Remedies Ltd continues to demonstrate strong fundamentals and market performance. The company operates within the Pharmaceuticals & Biotechnology sector and is classified as a microcap stock. Its current Mojo Score stands at 77.0, reflecting a solid 'Buy' grade, up from 68 previously. This score encapsulates various aspects of the company’s health and market sentiment.
Quality Assessment
The quality grade for Venus Remedies Ltd is assessed as average. This reflects a stable operational foundation with manageable risk factors. Notably, the company maintains a low debt-to-equity ratio, effectively zero, which reduces financial risk and enhances balance sheet strength. This conservative capital structure supports sustainable growth and shields the company from excessive leverage-related vulnerabilities.
Valuation Perspective
Venus Remedies Ltd’s valuation is currently attractive. The stock trades at a price-to-book value of 1.8, which is reasonable compared to its peers and historical averages. The company’s return on equity (ROE) is 10.5%, indicating efficient utilisation of shareholder funds. Furthermore, the price-to-earnings-to-growth (PEG) ratio stands at a notably low 0.1, signalling that the stock is undervalued relative to its earnings growth potential. This valuation profile suggests that the stock offers good value for investors seeking growth at a fair price.
Register here to know the latest call on Venus Remedies Ltd
- - Fundamental Analysis
- - Technical Signals
- - Peer Comparison
Financial Trend and Profitability
The financial trend for Venus Remedies Ltd is very positive. The company has reported remarkable growth in profitability metrics over recent periods. As of 24 December 2025, the net profit after tax (PAT) for the latest six months stands at ₹29.73 crores, reflecting an extraordinary growth of 528.54%. Earnings before interest and taxes (EBIT) or profit before tax less other income (PBT less OI) for the quarter is ₹24.78 crores, up by an astonishing 2073.68%. This consistent upward trajectory is further supported by four consecutive quarters of positive results, underscoring the company’s operational strength and earnings momentum.
Return on capital employed (ROCE) for the half year is at a healthy 13.99%, indicating efficient use of capital to generate profits. These financial trends highlight the company’s robust earnings growth and improving profitability, which are key drivers behind the current 'Buy' rating.
Technical Outlook
From a technical perspective, Venus Remedies Ltd exhibits a bullish trend. The stock price has shown strong momentum, with returns of +166.78% over the past year and +83.10% in the last three months. The six-month return is even more impressive at +90.07%, while the year-to-date (YTD) gain stands at +159.88%. These figures significantly outperform the broader BSE500 index over comparable periods, signalling strong investor confidence and positive market sentiment.
Despite a minor decline of 0.99% on the most recent trading day, the overall technical indicators remain favourable, supporting the stock’s upward trajectory. This bullish technical grade complements the fundamental strengths and valuation attractiveness, reinforcing the rationale for the 'Buy' rating.
Market Position and Outlook
Venus Remedies Ltd’s microcap status in the Pharmaceuticals & Biotechnology sector positions it as a nimble player with potential for substantial growth. The company’s low leverage, strong profitability growth, and attractive valuation metrics provide a solid foundation for future expansion. Investors looking for exposure to a fundamentally sound and technically strong stock in this sector may find Venus Remedies Ltd a compelling opportunity.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Investor Takeaway
For investors, the 'Buy' rating on Venus Remedies Ltd signals a favourable risk-reward profile based on current data. The company’s attractive valuation combined with strong financial growth and positive technical momentum suggests potential for continued capital appreciation. However, as with all microcap stocks, investors should consider liquidity and volatility factors alongside fundamental strengths.
In summary, Venus Remedies Ltd’s current rating reflects a balanced assessment of its quality, valuation, financial trend, and technical outlook as of 24 December 2025. This comprehensive view supports the recommendation to consider the stock as a buy candidate within a diversified portfolio.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
